AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

Search

Indivior PLC

Închisă

1,012 2.12

Rezumat

Modificarea prețului

24h

Curent

Minim

982

Maxim

1015

Indicatori cheie

By Trading Economics

Venit

-19M

47M

Vânzări

-33M

266M

P/E

Medie Sector

330

51.198

EPS

0.41

Marjă de profit

17.669

Angajați

1,030

EBITDA

-30M

76M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+1.53% upside

Dividende

By Dow Jones

Următoarele câștiguri

24 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

403M

1.2B

Deschiderea anterioară

1009.88

Închiderea anterioară

1012

Indivior PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 iun. 2025, 14:31 UTC

Câștiguri

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 20:33 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 iun. 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 iun. 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 iun. 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 iun. 2025, 16:35 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:34 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 iun. 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 iun. 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 iun. 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 iun. 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 iun. 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 iun. 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 iun. 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 iun. 2025, 14:12 UTC

Câștiguri

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 iun. 2025, 14:09 UTC

Câștiguri

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparație

Modificare preț

Indivior PLC Așteptări

Obiectiv de preț

By TipRanks

1.53% sus

Prognoză pe 12 luni

Medie 1,030.48 GBX  1.53%

Maxim 1,100 GBX

Minim 960.97 GBX

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIndivior PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.